Sugi Predict

Sugi Predict / Compounds / SCHEMBL5117237

SCHEMBL5117237

SCHEMBL5117237

COc1cc2c(cc1OC)-c1cc(Cl)nc(=O)n1CC2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 11/20 0.67
▸ MAPK1 P28482 9/20 0.67
▸ HSD17B10 Q99714 8/20 0.67
▸ TSHR P16473 8/20 0.67
▸ HPGD P15428 7/20 0.67
▸ MAPT P10636 4/20 0.67
▸ LMNA P02545 3/20 0.67
▸ KDM4E B2RXH2 12/20 0.65
▸ POLB P06746 4/20 0.64
▸ SMN1; SMN2 Q16637 3/20 0.64
▸ GAA P10253 1/20 0.61
▸ RAB9A P51151 1/20 0.61
▸ KMT2A Q03164 3/20 0.60
▸ USP2 O75604 2/20 0.60
▸ GPR84 Q9NQS5 2/20 0.60
▸ HTT P42858 1/20 0.60
▸ HK1 P19367 1/20 0.60
▸ HKDC1 Q2TB90 1/20 0.60
▸ ALOX15 P16050 1/20 0.60
▸ GLA P06280 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30640051 1.00 ALDH1A1 (0.67) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL30798841 0.94 ALDH1A1 (0.60) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL21621322 0.92 KMT2A (0.63) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL31620955 0.91 ALDH1A1 (0.57) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL25773448 0.86 GPR84 (0.77) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL25773161 0.86 GPR84 (0.77) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL14137941 0.85 ALDH1A1 (0.68) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL21621331 0.85 KMT2A (0.56) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL8147398 0.84 ALDH1A1 (0.67) ALDH1A1MAPK1HSD17B10TSHRHPGD
SCHEMBL14128843 0.82 ALDH1A1 (0.45) ALDH1A1MAPK1HSD17B10TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015354-A1 Solid State Forms of Ensifentrine CIPLA LIMITED (IN) 2026-01-15 — — US disclosed
EP-4610257-A1 CRYSTAL FORM OF ISOQUINOLINONE COMPOUND AND PREPARATION METHOD THEREFOR Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2025-09-03 — — EP disclosed
EP-4609864-A1 PHARMACEUTICAL COMPOSITION CONTAINING ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD THEREFOR Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2025-09-03 — — EP disclosed
WO-2025124462-A1 TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR AND PREPARATION AND USE THEREFOR 石家庄以岭药业股份有限公司 2025-06-19 — — WO disclosed
WO-2025124459-A1 TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR, AND PREPARATION AND USE THEREFOR 石家庄以岭药业股份有限公司 2025-06-19 — — WO disclosed
US-20240217974-A1 ISOQUINOLONE COMPOUND AND USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-07-04 — — US disclosed
US-20240217974-A1 ISOQUINOLONE COMPOUND AND USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-07-04 — — US disclosed
US-20240217974-A1 ISOQUINOLONE COMPOUND AND USE THEREOF JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-07-04 — — US disclosed
WO-2024127413-A1 SOLID STATE FORMS OF ENSIFENTRINE CIPLA LIMITED (IN) 2024-06-20 — — WO disclosed
WO-2024127413-A1 SOLID STATE FORMS OF ENSIFENTRINE CIPLA LIMITED (IN) 2024-06-20 — — WO disclosed
US-20030036542-A1 Derivatives of pyrimido[6.1-a]isoquinolin-4-one VERONA PHARMA PLC (GB) 2003-02-20 — — US disclosed
EP-1165558-A1 DERIVATIVES OF PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE Vernalis Limited (GB) 2002-01-02 — — EP disclosed
WO-2000058308-A1 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE VERNALIS LIMITED (GB) 2000-10-05 — — WO disclosed
EP-0973773-A1 PYRIMIDO-ISOQUINOLINE COMPOUNDS WITH ANTICONVULSIVE ACTION SMITHKLINE BEECHAM PLC (GB) 2000-01-26 — — EP disclosed
WO-1998045293-A1 PYRIMIDO-ISOQUINOLINE COMPOUNDS WITH ANTICONVULSIVE ACTION SMITHKLINE BEECHAM PLC (GB) 1998-10-15 — — WO disclosed
EP-0010759-B1 PYRIMIDO (6,1-A) ISOQUINOLIN-4-ONES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION IN MEDICAMENTS; INTERMEDIATES AND THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1986-07-30 — — EP disclosed
US-4598148-A HYPOTENSIVE AGENTS, BRONCHODIALTORS ANTIALLERGENS HOECHST AKTIENGESELLSCHAFT (DE) 1986-07-01 — — US disclosed
US-4482556-A HYPOTENSIVE AGENTS, BRONCHODILATORS, ANTIALLERGENS HOECHST AKTIENGESELLSCHAFT (DE) 1984-11-13 — — US disclosed
US-4400506-A CYCLIZATION OF A BARBITURIC ACID USING AN ACID CATALYST HOECHST AKTIENGESELLSCHAFT (DE) 1983-08-23 — — US disclosed
EP-0010759-A2 Pyrimido (6,1-a) isoquinolin-4-ones, process for their preparation and their application in medicaments; intermediates and their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1980-05-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030036542-A1 Derivatives of pyrimido[6.1-a]isoquinolin-4-one CXCR6, HRH1, HRH2 ALDH1A1 1001/4885MAPK1 2115/4885HSD17B10 3806/4885
US-20260015354-A1 Solid State Forms of Ensifentrine PDE3A, PDE5A, PDE3B ALDH1A1 2822/4885MAPK1 1831/4885HSD17B10 3505/4885
US-20240217974-A1 ISOQUINOLONE COMPOUND AND USE THEREOF CYP4A11, CYP11B2, NQO1 ALDH1A1 708/4885MAPK1 1255/4885HSD17B10 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.